Purpose: Although many tumor markers have been evaluated in relation to bladder cancer, none of these biomarkers reported to date has shown sufficient sensitivity and specificity for the detection of the whole spectrum of bladder cancer diseases in routine clinical practice. The limited value of the established prognostic markers requires analysis of new molecular parameters of interest for predicting the prognosis of bladder cancer patients.
INTRODUCTION
Bladder cancer consists of a broad spectrum of tumors that include transitional cell carcinomas, squamous cell carcinomas, and a few other tumor types. More than 90% of bladder cancers are transitional cell carcinomas and roughly 60% are low grade non-muscle invasive transitional cell carcinomas. The majority of these patients develop cancer recurrences after endoscopic resection, 16-25% with high-grade cancers. Approximately 10% of patients with non-muscle invasive bladder cancers subsequently develop invasive or metastatic disease. Almost 25% of patients with newly diagnosed bladder cancer have muscleinvasive disease, the vast majority being cancers of high histologic grade. Almost 50% of patients with muscle-invasive bladder cancer already have occult distant metastases. [1] [2] [3] However, conventional histopathologic evaluation, encompassing cancer grade and stage, is inadequate to accurately predict the behavior of most bladder cancers. The need to establish which non-muscle invasive cancers will recur or progress and which invasive cancers will metastasize has led to identification of a variety of potential prognostic markers for bladder cancer patients. Although precise reason why specific individuals get bladder cancer and progress to invasive disease with poor prognosis remains unknown, important determinants of population risk to bladder cancer may be mutation of proto-oncogenes and tumor suppressor genes, loss of heterozygosity for specific alleles, genetic polymorphism, and methylation patterns of promoter regions in specific genes.
Advances in molecular biology over the last decade succeeded in identification of many genetic alterations in bladder cancer.
Despite the apparent de novo clinical presentation of invasive bladder cancers, cytogenetic, and antigenic evidence supports the hypothesis that transitional cell carcinomas follow the general concept of multi-step carcinogenesis and proceed through two distinct genetic pathways responsible for generating different cancer morphologies. These are the inactivation of cyclindependent kinase inhibitors in low-grade transitional cell carcinoma and early p53-mediated abnormalities in high-grade transitional cell carcinoma. The progression of transitional cell carcinoma correlates with genetic instability and accumulation of collaborative genetic lesions. 4 Genetic variation in the human genome is an emerging resource to study cancer, a complex set of diseases characterized by both environmental and genetic contributions. It is becoming increasingly apparent that most of population-attributable cancer heritability is related not to the rare deleterious gene defects but to polymorphic variations in the DNA sequence. 5 This concept has been substantiated in a variety of cancer settings, particularly by the genetic epidemiology of bladder cancer.
Methylation of CpG islands is rare in normal cells. It plays a role in X-chromosome inactivation in females and genomic imprinting, and increases with age and in vitro cell culture.
Abnormal methylation of CpG islands can efficiently repress transcription of the associated gene in a manner akin to mutations and deletions, and act as one of the 'hits' in the Knudsen two-hit hypothesis for cancer generation. 6, 7 There are several examples of aberrant CpG island promoter hypermethylation of cancer suppressor genes, genes involved in cell-cell adhesion, and genes involved with DNA repair in relation to bladder cancer. [8] [9] [10] Examples in which one copy of a cancer suppressor gene is either mutated or lost and the wild-type copy is transcriptionally silenced by hypermethylation have been found. 11 It has recently been recognized that aberrant hyperme- These results suggest that the GSTT1-null genotype might not be a risk factor but a protective factor of bladder cancer.
Genes encoding a number of cytokines are polymorphic. 
EPIGENETIC ALTERATIONS
The is well conserved and recognizes a specific DNA sequence, but each has relatively divergent N-and C-terminal regions. 58 The RUNX gene family consists of three members, RUNX1/ AML1, RUNX2, and RUNX3. 59 , and p27
Kip1
. [77] [78] [79] [80] On the flip side, any genetic or epigenetic alteration of the TGF-β pathway can make normal cells vulnerable to tumorigenesis. 81, 82 Indeed, TGF-β receptors and SMADs are the main targets that are altered in numerous types of cancers, including pancreatic and colon cancers. 82 One of the downstream targets of TGF-β is p21, the central role it plays in CDK inhibition and cell cycle control. The ability to modulate p21 expression and thus regulation of the cell cycle is often considered to be an intrinsic characteristic of many tumor suppressor proteins, including p53, BRAC1, and SMADs. [83] [84] [85] [86] [87] RUNX3 is also an essential component of the TGF-β-mediated p21 induction that is critical for TGF-β-mediated cell growth inhibition. We revealed that 
